May 14, 2019 10:12 JST

Source: NEC Corporation

NEC Becomes the First Japanese Company to Join the TESLA Consortium's Fight Against Cancer

TOKYO, May 14, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has become the first Japanese company to join the Tumor neoantigEn SeLection Alliance (TESLA) founded and managed by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI). This global bioinformatics collaborative includes scientists from more than 35 of the leading neoantigen research groups in academia, nonprofit and industry. The goal is to find the best algorithms to predict which cancer neoantigens encoded in DNA and RNA can be recognized by and stimulate an immune response.

Individualized neoantigen vaccines, which are tailored to each patient's tumor, are one of most advanced cancer treatments to show great promise for activating the immune system to fight cancer whilst reducing the chances of autoimmune responses.

NEC was accepted into the TESLA consortium given the uniqueness of the company's Neoantigen Prediction System. The prediction system utilizes NEC's cutting-edge AI technology, "NEC the WISE"(1), to identify and prioritize patient-specific neoantigens. NEC comprehensively evaluates candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.

"By participating in this consortium, NEC will be able to collaborate with the world's leading research organizations and potentially improve the chances of survival for cancer patients with this new treatment option," said Osamu Fujikawa, Senior Vice President, NEC Corporation. "NEC focuses on the provision of social solutions and continues efforts to strengthen its next-generation healthtech businesses," he added.

(1) NEC the WISE
NEC the WISE is a term for the Company's cutting-edge portfolio of AI technologies.

Contact:
NEC
Seiichiro Toda        
s-toda@cj.jp.nec.com
+81-3-3798-6511
Source: NEC Corporation
Sectors: Cloud & Enterprise, BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Executive Appointments in Connection with the Establishment of NESIC Holdings
June 23 2025 18:22 JST
 
NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment
June 18 2025 12:40 JST
 
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 months with Individualized Cancer Vaccine TG4050
June 02 2025 16:56 JST
 
IFS and NEC Strengthen their Strategic Partnership to Create New Value
May 30 2025 09:11 JST
 
NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally
April 28 2025 15:03 JST
 
NEC invests in U.S.-based "Geodesic Alliance Fund" aiming to strengthen economic security business
April 24 2025 09:23 JST
 
NEC Face Recognition Ranks First in NIST Accuracy Testing
April 09 2025 10:09 JST
 
NEC Orchestrating Future Fund invests in Rescale, Inc., provider of a leading digital engineering platform for cloud high-performance computing (HPC)
April 08 2025 15:42 JST
 
SITA and NEC Collaborate to Drive Global Adoption of Digital Identities in Travel
April 08 2025 15:11 JST
 
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
April 01 2025 15:15 JST
 
More Press release >>

Latest Press Release


More Latest Release >>